Table 3.
Changes in PSA by T formulation and CaP status
| T formulation | Baseline PSA (ng/mL) | Final follow-Up PSA (ng/mL) | P value |
|---|---|---|---|
| Mean (SD) | Mean (SD) | ||
| Gels (n = 47) | 0.90 (0.72) | 1.02 (0.83) | 0.52 |
| With CaP (n = 6) | 0.06 (0.12) | 0.01(0.001) | 0.51 |
| Without CaP (n = 41) | 1.05 (0.67) | 1.23 (0.76) | 0.43 |
| Injectables (n = 57) | 0.73 (0.53) | 0.73 (0.47) | 0.99 |
| With CaP (n = 4) | 0.01 (0.00) | 0.01 (0.00) | 1.00 |
| Without CaP (n = 53) | 0.78 (0.51) | 0.86 (0.39) | 0.55 |
| Pellets (n = 74) | 1.24 (1.48) | 1.41 (1.31) | 0.54 |
| With CaP (n = 8) | 0.65 (1.45) | 0.04 (0.05) | 0.81 |
| Without CaP (n = 66) | 1.31 (1.48) | 1.46 (1.28) | 0.60 |
CaP = protstate cancer; PSA = prostate-specific antigen; SD = standard deviation; T = testosterone.